Dyne Therapeutics closed at $18.54 on Nov 4, up 2.71%, 30.8% below its 52-week closing high. Volume of 3.7M shares was 1.33× its 20-day average (above normal).
Split-adjusted performance: +20.4% over one month, -1.6% over six months, -23.1% over one year.
Short interest was 25.5M shares at the Oct 15 settlement, down 2.0% from the prior report (14.6% of float, 7.4 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| DYNDyne Therapeutics | $18.54 | +2.71% | −1.6% | — | — | — | $3.46B | |
| ELVNEnliven Therapeutics | $47.25 | +5.40% | +14.7% | — | — | — | $3.46B | Compare |
| VKTXViking Therapeutics | $27.97 | +7.21% | −13.4% | — | — | — | $3.57B | Compare |
| OGNOrganon & | $13.83 | −0.14% | +3.1% | −1.7% | 10.4% | 17.1 | $3.63B | Compare |
| VRDNViridian Therapeutics | $29.06 | +15.53% | +65.7% | +278.7% | −39726.8% | — | $3.29B | Compare |
| AMLXAmylyx Pharmaceuticals | $29.40 | +0.68% | +83.1% | — | — | — | $3.69B | Compare |
| IRONDisc Medicine | $83.28 | +2.61% | +21.3% | — | — | — | $3.70B | Compare |
| ACADAcadia Pharmaceuticals | $21.47 | +4.38% | 0.0% | +16.4% | 10.2% | 9.7 | $3.70B | Compare |
| PBLSParabilis Medicines | $30.36 | +3.79% | — | — | −45239.9% | — | $3.75B | Compare |
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
